• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黏多糖贮积症心脏表现的早期诊断和管理:儿科和成人心脏病学家实用指南。

Early diagnosis and management of cardiac manifestations in mucopolysaccharidoses: a practical guide for paediatric and adult cardiologists.

机构信息

U.O. Cardiologia ASST Monza, 20900, Monza, Italy.

Center of Paediatric Cardiology and Adult Cardiac Genetic Disease, ASL BT, Via Padre Pio, 76125, Trani, (BT), Italy.

出版信息

Ital J Pediatr. 2018 Nov 16;44(Suppl 2):122. doi: 10.1186/s13052-018-0560-3.

DOI:10.1186/s13052-018-0560-3
PMID:30442163
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6238246/
Abstract

Mucopolysaccharidoses (MPS) are a group of hereditary disorders caused by lysosomal storage of glycosaminoglycans (GAGs) and characterized by a wide variability of phenotypes from severe fetal-neonatal forms to attenuated diseases diagnosed in adult individuals. The clinical picture generally worsens with age due to progressive storage involving mucosal tissue, upper airways and lungs, bones and joints, central and peripheral nervous system, heart, liver, eye, and ear. Cardiac storage of GAGs involves valves, heart muscle, and vessels (particularly the coronary arteries), and can be specific in relation to different MPS types and enzyme defects. MPS I, II, and VI are those with the most severe cardiac involvement. The cardiologist is a key figure in MPS, and their role is expanding from cardiac-specific management to early diagnosis when the mild disease phenotypes have not yet been recognized by other specialists. Familial and personal history, electrocardiography, imaging, and laboratory findings represent important steps in the clinical investigation of these patients. New treatments have led to an increased need for cardiologists to be on the lookout for MPS patients since they can significantly improve the lives of people with MPS if they suspect the diagnosis and refer them for enzyme replacement therapy or bone marrow transplantation.

摘要

黏多糖贮积症(MPS)是一组由溶酶体贮积糖胺聚糖(GAG)引起的遗传性疾病,其表型具有广泛的变异性,从严重的胎儿-新生儿形式到成人诊断的衰减疾病。由于涉及粘膜组织、上呼吸道和肺部、骨骼和关节、中枢和周围神经系统、心脏、肝脏、眼睛和耳朵的进行性贮积,临床症状通常会随着年龄的增长而恶化。GAG 在心脏中的贮积涉及瓣膜、心肌和血管(特别是冠状动脉),并且可以与不同的 MPS 类型和酶缺陷相关。MPS I、II 和 VI 是心脏受累最严重的类型。心脏病专家是 MPS 中的关键人物,他们的角色正在从心脏特异性管理扩展到早期诊断,当其他专家尚未认识到轻度疾病表型时。家族史和个人史、心电图、影像学和实验室发现是这些患者临床研究的重要步骤。新的治疗方法导致心脏病专家需要更加关注 MPS 患者,因为如果他们怀疑诊断并将其转介进行酶替代疗法或骨髓移植,这些治疗方法可以显著改善 MPS 患者的生活。

相似文献

1
Early diagnosis and management of cardiac manifestations in mucopolysaccharidoses: a practical guide for paediatric and adult cardiologists.黏多糖贮积症心脏表现的早期诊断和管理:儿科和成人心脏病学家实用指南。
Ital J Pediatr. 2018 Nov 16;44(Suppl 2):122. doi: 10.1186/s13052-018-0560-3.
2
[Cardiologists and mucopolysaccharidoses. Recommendations of GICEM (Cardiology Experts on Metabolic Disease Italian Group) for diagnosis, follow-up and cardiological management].[心脏病专家与黏多糖贮积症。意大利代谢性疾病心脏病学专家小组(GICEM)关于诊断、随访及心脏管理的建议]
G Ital Cardiol (Rome). 2017 Sep;18(9):638-649. doi: 10.1714/2741.27947.
3
Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI.黏多糖贮积症 I 型、II 型、IVA 型和 VI 型患者的心脏结构与功能以及酶替代疗法的效果
Mol Genet Metab. 2016 Apr;117(4):431-7. doi: 10.1016/j.ymgme.2016.02.003. Epub 2016 Feb 16.
4
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.黏多糖贮积症患者的心脏疾病:临床表现、诊断与治疗。
J Inherit Metab Dis. 2011 Dec;34(6):1183-97. doi: 10.1007/s10545-011-9359-8. Epub 2011 Jul 9.
5
Cardiac structural involvement in mucopolysaccharidoses.黏多糖贮积症中的心脏结构受累情况。
Cardiology. 2002;98(1-2):18-20. doi: 10.1159/000064674.
6
[Neurologic manifestations in mucopolysaccharidoses].[黏多糖贮积症的神经学表现]
Arch Pediatr. 2014 Jun;21 Suppl 1:S14-21. doi: 10.1016/S0929-693X(14)72254-7.
7
Ocular features in mucopolysaccharidosis: diagnosis and treatment.黏多糖贮积症的眼部特征:诊断与治疗。
Ital J Pediatr. 2018 Nov 16;44(Suppl 2):125. doi: 10.1186/s13052-018-0559-9.
8
Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs.成人黏多糖贮积症患者的心脏问题:当前认知与新出现的需求
Heart. 2016 Aug 15;102(16):1257-62. doi: 10.1136/heartjnl-2015-309258. Epub 2016 Apr 21.
9
Cardiac manifestations of the mucopolysaccharidoses.黏多糖贮积症的心脏表现
Circulation. 1975 Oct;52(4):700-5. doi: 10.1161/01.cir.52.4.700.
10
Overview of the mucopolysaccharidoses.黏多糖贮积症概述。
Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v4-12. doi: 10.1093/rheumatology/ker394.

引用本文的文献

1
"Mucopolysaccharidosis syndrome in a 9-Year-old boy: oral-dental management and diagnostic considerations": a case report.《9 岁男孩黏多糖贮积症:口腔牙科管理和诊断注意事项》:病例报告。
BMC Oral Health. 2024 Sep 27;24(1):1140. doi: 10.1186/s12903-024-04859-6.
2
Mucopolysaccharidosis-Plus Syndrome: Is This a Type of Mucopolysaccharidosis or a Separate Kind of Metabolic Disease?黏多糖贮积症伴多发畸形综合征:这是一种黏多糖贮积症,还是一种独立的代谢疾病?
Int J Mol Sci. 2024 Sep 4;25(17):9570. doi: 10.3390/ijms25179570.
3
Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model.

本文引用的文献

1
[Cardiologists and mucopolysaccharidoses. Recommendations of GICEM (Cardiology Experts on Metabolic Disease Italian Group) for diagnosis, follow-up and cardiological management].[心脏病专家与黏多糖贮积症。意大利代谢性疾病心脏病学专家小组(GICEM)关于诊断、随访及心脏管理的建议]
G Ital Cardiol (Rome). 2017 Sep;18(9):638-649. doi: 10.1714/2741.27947.
2
Myocardial deformation in pediatric patients with mucopolysaccharidoses: A two-dimensional speckle tracking echocardiography study.黏多糖贮积症患儿的心肌形变:一项二维斑点追踪超声心动图研究
Echocardiography. 2017 Feb;34(2):240-249. doi: 10.1111/echo.13444. Epub 2017 Jan 10.
3
拉罗尼酶与金雀异黄素联合治疗 Mucopolysaccharidosis Type I 模型鼠的疗效。
Int J Mol Sci. 2024 Feb 17;25(4):2371. doi: 10.3390/ijms25042371.
4
Evaluation of cardiac findings in mucopolysaccharidosis.黏多糖贮积症的心脏表现评估。
Int J Cardiovasc Imaging. 2024 Jan;40(1):73-78. doi: 10.1007/s10554-023-02983-y. Epub 2023 Oct 17.
5
Mucopolysaccharidosis: What Pediatric Rheumatologists and Orthopedics Need to Know.黏多糖贮积症:儿科风湿病学家和骨科医生需要了解的内容。
Diagnostics (Basel). 2022 Dec 27;13(1):75. doi: 10.3390/diagnostics13010075.
6
Drug Repositioning Applied to Cardiovascular Disease in Mucopolysaccharidosis.药物重新定位在黏多糖贮积症心血管疾病中的应用
Life (Basel). 2022 Dec 12;12(12):2085. doi: 10.3390/life12122085.
7
Unmet Cardiac Clinical Needs in Adult Mucopolysaccharidoses.成人黏多糖贮积症未满足的心脏临床需求
Front Cardiovasc Med. 2022 Jun 10;9:907175. doi: 10.3389/fcvm.2022.907175. eCollection 2022.
8
Pre-operative Considerations in Adult Mucopolysaccharidosis Patients Planned for Cardiac Intervention.计划进行心脏介入治疗的成年黏多糖贮积症患者的术前注意事项。
Front Cardiovasc Med. 2022 Apr 4;9:851016. doi: 10.3389/fcvm.2022.851016. eCollection 2022.
9
Non-Cardiac Cause of Death in Selected Group Children with Cardiac Pathology: A Retrospective Single Institute Study.特定心脏病理患儿的非心脏死因:一项单机构回顾性研究
Children (Basel). 2022 Mar 2;9(3):335. doi: 10.3390/children9030335.
10
Surgical Management of Valvular Heart Disease in Mucopolysaccharidoses: A Review of Literature.黏多糖贮积症中瓣膜性心脏病的外科治疗:文献综述
Biomedicines. 2022 Feb 4;10(2):375. doi: 10.3390/biomedicines10020375.
Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.
血管紧张素受体阻断介导的对I型黏多糖贮积症心脏和颅面病理的改善作用。
J Inherit Metab Dis. 2017 Mar;40(2):281-289. doi: 10.1007/s10545-016-9988-z. Epub 2016 Oct 14.
4
Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome).IVA型黏多糖贮积症(Morquio - A综合征)患者的心脏和心血管受累情况
PLoS One. 2016 Sep 9;11(9):e0162612. doi: 10.1371/journal.pone.0162612. eCollection 2016.
5
Unexpected coronary artery findings in mucopolysaccharidosis. Report of four cases and literature review.黏多糖贮积症的冠状动脉意外发现。4 例报告及文献复习。
Cardiovasc Pathol. 2014 May-Jun;23(3):145-51. doi: 10.1016/j.carpath.2014.01.001. Epub 2014 Jan 10.
6
Management of aortic stenosis in mucopolysaccharidosis type I.黏多糖贮积症 I 型中主动脉瓣狭窄的管理
Int J Cardiol. 2014 Apr 1;172(3):e430-1. doi: 10.1016/j.ijcard.2013.12.233. Epub 2014 Jan 11.
7
Management of mucopolysaccharidosis type IH (Hurler's syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution's experience.婴儿期起病且伴有严重扩张型心肌病的黏多糖贮积症 IH 型(胡尔勒综合征)的治疗:单中心经验。
J Inherit Metab Dis. 2013 Mar;36(2):263-70. doi: 10.1007/s10545-012-9500-3. Epub 2012 Jun 21.
8
Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator.黏多糖贮积症中骨骼和结缔组织受累的发病机制:糖胺聚糖贮积仅仅是诱因。
Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v13-8. doi: 10.1093/rheumatology/ker395.
9
Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP).MPS VI(黏多糖贮积症 VI 型)临床监测计划(CSP)的设计、基线特征和早期发现。
J Inherit Metab Dis. 2013 Mar;36(2):373-84. doi: 10.1007/s10545-011-9410-9. Epub 2011 Nov 30.
10
Double-valve replacement for Scheie's syndrome subtype mucopolysaccaridosis type 1-S.Scheie 综合征亚型黏多糖贮积症 1-S 行双瓣置换术。
Ann Thorac Surg. 2011 Sep;92(3):1104-5. doi: 10.1016/j.athoracsur.2011.03.051.